What is it about?
As regards such a study has not been conducted at Mazandaran Heart Center recently, and the specific conditions of patients referred to the center, we decided to perform this study with the aim of determining the immunogenicity of hepatitis B vaccine in chronic HD patients in Mazandaran Heart Center in Iran, to be aware of the results of this study and take the necessary actions to prevent the disease and increase the safety in these patients with the cooperation of staff working in this center.
Featured Image
Why is it important?
Based on the observed information, the immunogenicity of hepatitis B vaccine in Mazandaran Heart Center HD patients is moderate to low that the rate of response to vaccine were reasonable according to the previous studies.
Perspectives
Given that hepatitis B is a major problem for dialysis patients and by all measures which is done to reduce the prevalence of it, the risk of the disease, still extremely limiting the patients on dialysis. It is recommended to comply with quality control issues in the hemodialysis unit to reduce transmission of the HBV and reduce the incidence of that in Hemodialysis Patients, moreover by conducting comprehensive researches, take a step to find more effective methods of prevention and treatment.
Amir Shamshirian
Mazandaran University of Medical Sciences
Read the Original
This page is a summary of: Evaluation of Immunogenicity of Hepatitis B Vaccine in Hemodialysis Patients at Mazandaran Heart Center, Iran, Biomedical & Pharmacology Journal, June 2017, Oriental Scientific Publishing Company,
DOI: 10.13005/bpj/1141.
You can read the full text:
Contributors
The following have contributed to this page
